Metastatic Breast Cancer | Tumor

CURE’s metastatic breast cancer page features the latest cancer news and updates on metastatic breast cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in metastatic breast cancer.

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

February 19th 2025, 8:00pm

Article

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.

Are We at Risk of Losing Our Breast Cancer Community?

February 14th 2025, 6:00pm

Article

I found community after my metastatic breast cancer diagnosis, but recent discord in cancer support groups makes me fear we're losing these vital connections.

An Expert Explains the Enhertu Approval in HER2-Low and -Ultralow Breast Cancer

February 12th 2025, 2:00pm

Video

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.

Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025, 4:00pm

Article

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

Strutting Into Year 11 With Metastatic Breast Cancer

January 30th 2025, 6:00pm

Article

After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with confidence and self-advocacy.

Itovebi-Based Treatment Has OS Benefit in PIK3CA+ HR+/HER2– Breast Cancer

January 30th 2025, 2:00pm

Article

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer

January 28th 2025, 12:22am

Article

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.

FDA Approves Datroway for HR+, HER2- Breast Cancer

January 17th 2025, 6:54pm

Article

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

Top Breast Cancer Stories in 2024

December 31st 2024, 4:00pm

Article

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and side effect management, among others.

CDK4/6 Inhibitor Combos Miss Survival Goal in Metastatic Breast Cancer Subset

December 12th 2024, 8:43pm

Article

No significant survival benefits were found when comparing three CDK4/6 inhibitor combinations during initial treatment for HR-positive, HER2-negative metastatic breast cancer.